Skip to content

DMT: all studies

Page 102 of 160: studies 1,011 to 1,020 of 1,593, newest first. Back to the DMT overview

Research

A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines.

Journal of Biological Chemistry October 1, 2023 Xue Chen, Jing Li, Lisa Yu et al. 13 citations

Psychedelic indolethylamines have emerged as potential medicines to treat several psychiatric pathologies. Natural sources of these compounds include 'magic mushrooms' (Psilocybe spp.), plants used to prepare ayahuasca, and toads. The skin and parotid glands of certain toads accumulate a variety of specialized metabolites including toxic guanidine alkaloids, lipophilic alkaloids, poisonous...

DOI: 10.1016/j.jbc.2023.105231 (opens in new tab) Full text (opens in new tab) N-methyltransferase Rhinella marina Drug discovery Enzyme kinetics +11

Desenvolvimento de método baseado em Toxicologia Analítica Verde para determinação dos componentes ativos da ayahuasca em cabelo

September 27, 2023 Fabiana Pereira Santos

A ayahuasca é uma bebida alucinógena originária na América do Sul, utilizada por indígenas em rituais xamânicos. É obtida através da fermentação de duas plantas, a folha da P. viridis, na qual é obtida a dimetiltriptamina (DMT), substância responsável pelos efeitos alucinógenos e o cipó B. caapi que contém β-carbolinas (harmina, harmalina e tetraidro-harmina). As β-carbolinas impedem a...

Medicalisation of Ayahuasca as a Depression Treatment

The Maastricht Journal of Liberal Arts September 19, 2023 Elena Gomel Cordeiro

This paper examines the possible consequences of medicalising the psychedelic Ayahuasca to be used as a treatment for depression. Through a science and technology studies (STS) understanding of the social construction of scientific facts, I consider how traditional indigenous uses of Ayahuasca are translated into Western medicine. Two special points of attention are: (1) the cultural...

DOI: 10.26481/mjla.2023.v14.912 (opens in new tab) Ayahuasca Indigenous Biomedicine Medicalization +7

Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders.

ACS Medicinal Chemistry Letters September 14, 2023 Robert B. Kargbo 3 citations

Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth and enhance neural structures, show promise in mitigating these changes. They activate key biological targets, including AMPA receptors, TrkB, and mTOR. Substances like ketamine, scopolamine, N,N-dimethyltryptamine, and rapastinel have...

Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training

American Journal of Psychiatry Residents Journal September 8, 2023 Lawrence Canale, Dhvanit Raval, Preet Chatha et al.

Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...

EVALUATION OF THE THERAPEUTIC NEUROTOXIC EFFECTS OF THE USE OF AYAHUASCA BY DEPRESSIVE PATIENTS

Revista Contemporânea September 5, 2023 Catarina Rodrigues Damasceno Murucci, Rita de Cássia Ramos Queiroz de Freitas, Grazielly Ribeiro Viana et al.

Ayahuasca is a tea used in original indigenous rituals with the aim of expanding the mind and consciousness. Some studies have pointed to Ayahuasca as a potent antidepressant with reduced side effects when compared to other conventional synthetic allopathic treatments. Over the years, tea has come to be known by both the popular community and the scientific community. The species used are...

DOI: 10.56083/rcv3n9-011 (opens in new tab) Ayahuasca Pharmacology Harmaline Traditional medicine +1

The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits

Journal of Applied Toxicology August 30, 2023 Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al. 2 citations

Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Journal of Psychoactive Drugs August 24, 2023 Stanley Wong, An Yi Yu, Nicholas Fabiano et al. 11 citations

There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells

Current Issues in Molecular Biology August 15, 2023 Gregory Ian Robinson, Dongping Li, Bo Wang et al. 20 citations

Intestinal inflammation and dysbiosis can lead to inflammatory bowel diseases (IBD) and systemic inflammation, affecting multiple organs. Developing novel anti-inflammatory therapeutics is crucial for preventing IBD progression. Serotonin receptor type 2A (5-HT2A) ligands, including psilocybin (Psi), 4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), and ketanserin (Ket), along with transient...

DOI: 10.3390/cimb45080427 (opens in new tab) Serotonin 5-HT Receptor Transient computer programming Cell biology +2

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...